Alzheon, Inc. (ALZH): Price and Financial Metrics
ALZH Stock Price Chart More Charts
ALZH Price/Volume Stats
Alzheon, Inc. (ALZH) Company Bio
Alzheon, Inc. operates as a clinical stage biopharmaceutical company in the United States and internationally. The company’s lead product is ALZ-801, an orally administered inhibitor of beta amyloid misfolding, which is in Phase III clinical trial for treating Alzheimer’s disease and other neurological disorders. Its lead preclinical candidate compound includes ALZ-1903, a chemical entity and potent inhibitor of beta amyloid misfolding. The company was founded in 2013 and is based in Framingham, Massachusetts.